Indeed, our results are similar to those of Liu et al. who reported an up-regulation of pERK in GC cells treated with the mTOR inhibitor everolimus and the reversal of resistance to everolimus by combining it with the MEK inhibitor trametinib32. This evidence concerns the gene MAP2K7 and gastric cancer.